LETTER TO THE EDITOR Screening for Fingolimod Associated Macular Oedema: Experience Versus Guidelines

We report adherence to United Kingdom national guidelines on surveillance for Fingolimod associated macular oedema (FAME) and the impact on clinical services at our unit. We conducted a 9-month study, measuring referral interval, visual function and performing OCT scans for all patients referred for...

Descripción completa

Detalles Bibliográficos
Autores principales: Moosavi, R, Bremner, F, Acheson, J
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Bentham Open 2014
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4192831/
https://www.ncbi.nlm.nih.gov/pubmed/25317219
http://dx.doi.org/10.2174/1874364101408010073
_version_ 1782338849387577344
author Moosavi, R
Bremner, F
Acheson, J
author_facet Moosavi, R
Bremner, F
Acheson, J
author_sort Moosavi, R
collection PubMed
description We report adherence to United Kingdom national guidelines on surveillance for Fingolimod associated macular oedema (FAME) and the impact on clinical services at our unit. We conducted a 9-month study, measuring referral interval, visual function and performing OCT scans for all patients referred for FAME surveillance. 38 patients in total were seen, representing 9% of all new ophthalmic referrals during the study period. 26% were seen between 2 and 4 months after starting Fingolimod treatment, 74% between 3 and 4 months after starting Fingolimod treatment. The impact on clinical services is discussed.
format Online
Article
Text
id pubmed-4192831
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher Bentham Open
record_format MEDLINE/PubMed
spelling pubmed-41928312014-10-14 LETTER TO THE EDITOR Screening for Fingolimod Associated Macular Oedema: Experience Versus Guidelines Moosavi, R Bremner, F Acheson, J Open Ophthalmol J Article We report adherence to United Kingdom national guidelines on surveillance for Fingolimod associated macular oedema (FAME) and the impact on clinical services at our unit. We conducted a 9-month study, measuring referral interval, visual function and performing OCT scans for all patients referred for FAME surveillance. 38 patients in total were seen, representing 9% of all new ophthalmic referrals during the study period. 26% were seen between 2 and 4 months after starting Fingolimod treatment, 74% between 3 and 4 months after starting Fingolimod treatment. The impact on clinical services is discussed. Bentham Open 2014-10-3 /pmc/articles/PMC4192831/ /pubmed/25317219 http://dx.doi.org/10.2174/1874364101408010073 Text en © Moosavi et al.; Licensee Bentham Open. http://creativecommons.org/licenses/by-nc/3.0/ This is an open access article licensed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted, non-commercial use, distribution and reproduction in any medium, provided the work is properly cited.
spellingShingle Article
Moosavi, R
Bremner, F
Acheson, J
LETTER TO THE EDITOR Screening for Fingolimod Associated Macular Oedema: Experience Versus Guidelines
title LETTER TO THE EDITOR Screening for Fingolimod Associated Macular Oedema: Experience Versus Guidelines
title_full LETTER TO THE EDITOR Screening for Fingolimod Associated Macular Oedema: Experience Versus Guidelines
title_fullStr LETTER TO THE EDITOR Screening for Fingolimod Associated Macular Oedema: Experience Versus Guidelines
title_full_unstemmed LETTER TO THE EDITOR Screening for Fingolimod Associated Macular Oedema: Experience Versus Guidelines
title_short LETTER TO THE EDITOR Screening for Fingolimod Associated Macular Oedema: Experience Versus Guidelines
title_sort letter to the editor screening for fingolimod associated macular oedema: experience versus guidelines
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4192831/
https://www.ncbi.nlm.nih.gov/pubmed/25317219
http://dx.doi.org/10.2174/1874364101408010073
work_keys_str_mv AT moosavir lettertotheeditorscreeningforfingolimodassociatedmacularoedemaexperienceversusguidelines
AT bremnerf lettertotheeditorscreeningforfingolimodassociatedmacularoedemaexperienceversusguidelines
AT achesonj lettertotheeditorscreeningforfingolimodassociatedmacularoedemaexperienceversusguidelines

Ejemplares similares